remoxipride

Summary

Summary: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.

Top Publications

  1. von Bahr C, Wiesel F, Movin G, Eneroth P, Jansson P, Nilsson L, et al. Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers. Psychopharmacology (Berl). 1991;103:443-8 pubmed
    Six female and six male healthy volunteers received 100 mg remoxipride, 200 mg sulpiride and placebo as single oral doses in a double blind trial with a randomized crossover design...
  2. Lidow M, Goldman Rakic P. A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex. Proc Natl Acad Sci U S A. 1994;91:4353-6 pubmed
    The potencies of the major neuroleptics used in the treatment of schizophrenia, including haloperidol and remoxipride, correlate with their ability to bind D2-dopaminergic receptors in subcortical structures...
  3. Files F, Denning C, Samson H. Effects of the atypical antipsychotic remoxipride on alcohol self-administration. Pharmacol Biochem Behav. 1998;59:281-5 pubmed
    b>Remoxipride is a dopamine (DA) D2 antagonist that produces fewer of the side effects normally associated with chronic DA antagonist administration...
  4. Erve J, Svensson M, von Euler Chelpin H, Klasson Wehler E. Characterization of glutathione conjugates of the remoxipride hydroquinone metabolite NCQ-344 formed in vitro and detection following oxidation by human neutrophils. Chem Res Toxicol. 2004;17:564-71 pubmed
    b>Remoxipride is an atypical antipsychotic displaying selective binding to the dopamine D2 receptor. Several cases of aplastic anemia led to the withdrawal of remoxipride from the market in December 1993...
  5. Movin Osswald G, Hammarlund Udenaes M, von Bahr C, Eneroth P, Walton Bowen K. Influence of the dosing interval on prolactin release after remoxipride. Br J Clin Pharmacol. 1995;39:503-10 pubmed
    1. The prolactin response following administration of the D2-dopamine receptor antagonist remoxipride was studied in eight healthy male volunteers...
  6. Sjöqvist R, Graffner C, Ekman I, Sinclair W, Woods J. In vivo validation of the release rate and palatability of remoxipride-modified release suspension. Pharm Res. 1993;10:1020-6 pubmed
    b>Remoxipride, a D2-dopamine receptor antagonist, is well tolerated and completely absorbed after oral administration...
  7. Widman M, Nilsson L, Bryske B, Lundstrom J. Disposition of remoxipride in different species. Species differences in metabolism. Arzneimittelforschung. 1993;43:287-97 pubmed
    The pharmacokinetics and metabolism of the new antipsychotic agent remoxipride ((S)-(-)-3-bromo-N(-)[(1-ethyl-2-pyrrolidinyl)methyl]-2, 6-dimethoxybenzamide, FLA731(-), Roxiam, CAS 80125-14-0) was studied in rodents (mice, rats, hamsters)..
  8. Main D, Waterman A, Kilpatrick I, Jones A. An assessment of the peripheral antinociceptive potential of remoxipride, clonidine and fentanyl in sheep using the forelimb tourniquet. J Vet Pharmacol Ther. 1997;20:220-8 pubmed
    ..of the intravenous regional anaesthesia technique was used to assess the peripheral antinociceptive effect of remoxipride, clonidine and fentanyl...
  9. Awad A, Lapierre Y, Angus C, Rylander A. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. J Psychiatry Neurosci. 1997;22:244-8 pubmed
    In a large, multicenter, double-blind study of the effect of haloperidol and the atypical antipsychotic remoxipride on improvement of negative symptoms in schizophrenia, quality of life was also assessed using a modified version of the ..

More Information

Publications106 found, 100 shown here

  1. Czachowski C, Santini L, Legg B, Samson H. Separate measures of ethanol seeking and drinking in the rat: effects of remoxipride. Alcohol. 2002;28:39-46 pubmed
    b>Remoxipride, a dopamine D(2) antagonist, decreases responding that results in the presentation of small amounts (approximately 0.1 ml) of ethanol in limited-access paradigms...
  2. van den Brink W, Wong Y, Gülave B, van der Graaf P, de Lange E. Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling. AAPS J. 2017;19:274-285 pubmed publisher
    ..The aim of this study was to investigate the effect of the dopamine D2 antagonist remoxipride on the neuroendocrine system. Different doses of remoxipride (0, 0.7, 5...
  3. Saletu B, Küfferle B, Anderer P, Grünberger J, Steinberger K. EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol. Eur Neuropsychopharmacol. 1990;1:27-36 pubmed
    ..Treatment of schizophrenics with predominantly positive symptoms with 2 different neuroleptics such as remoxipride and haloperidol resulted also in differential effects on brain activity: while haloperidol augmented delta/..
  4. Segerberg Konttinen M, Vuori E, Lukkari I, Penttila A. Fatal intoxication by Remoxipride. J Forensic Sci. 1989;34:500-3 pubmed
    The case history and toxicologic findings of a 23-year-old woman who committed suicide with Remoxipride are described. Remoxipride is a recently developed neuroleptic drug of the benzamide type...
  5. Mechan A, Esteban B, O Shea E, Elliott J, Colado M, Green A. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Br J Pharmacol. 2002;135:170-80 pubmed
    ..5. The dopamine D(2) antagonist remoxipride (10 mg kg(-1)) did not alter MDMA-induced hyperthermia, but the D(1) antagonist SCH 23390 (0.3 - 2...
  6. Andersen J, Kørner A, Ostergaard P, Fensbo C, Birket Smith M, Thiesen S, et al. A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia. Acta Psychiatr Scand Suppl. 1990;358:104-7 pubmed
    ..psychosis were admitted to a multicentre, double-blind controlled study to evaluate the efficacy and safety of remoxipride in comparison to haloperidol...
  7. Zhu M, Juorio A, Paterson I, Boulton A. Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. Eur J Pharmacol. 1993;238:157-64 pubmed
    ..1 mg/kg) increased striatal AADC activity (by 25 and 26% above controls) and similar effects were observed with remoxipride (0.5-4 mg/kg) (by 18-27% above controls)...
  8. Inayat Hussain S, McGuinness S, Johansson R, Lundstrom J, Ross D. Caspase-dependent and -independent mechanisms in apoptosis induced by hydroquinone and catechol metabolites of remoxipride in HL-60 cells. Chem Biol Interact. 2000;128:51-63 pubmed
    The hydroquinone and catechol like metabolites, NCQ344 and NCQ436 respectively, of the antipsychotic remoxipride have recently been demonstrated to induce apoptosis in myeloperoxidase (MPO)-rich human bone marrow progenitor and HL-60 ..
  9. Morrison D, Englund A, Lawrie V, Lewander T, Schlachet A, Westerbergh S. Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride. Acta Psychiatr Scand Suppl. 1990;358:164-9 pubmed
    ..low incidences of both transient treatment-emergent changes and changes present at last rating for both remoxipride and haloperidol...
  10. Mendis T, Mohr E, George A, Rusk I, Gray P, Grimes J. Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride. Mov Disord. 1994;9:197-200 pubmed
    Current treatment strategies for levodopa-induced psychosis in Parkinson's disease have had limited success. Remoxipride, a selective D2 receptor antagonist, was administered in an open label pilot study to seven parkinsonian patients ..
  11. Nimmo S, Kennedy B, Tullett W, Blyth A, Dougall J. Drug-induced hyperthermia. Anaesthesia. 1993;48:892-5 pubmed
    ..We describe three cases of drug-induced hyperthermia, discuss their aetiology and management, with both general measures and therapies designed to redress neurotransmitter imbalance. ..
  12. Rammsayer T. On dopaminergic modulation of temporal information processing. Biol Psychol. 1993;36:209-22 pubmed
    ..In a double-blind design, either 3 mg of haloperidol, 150 mg of remoxipride, or placebo were administered in a single oral dose...
  13. Pajonk F, Holzbach R, Naber D. Comparing the efficacy of atypical antipsychotics in open uncontrolled versus double-blind controlled trials in schizophrenia. Psychopharmacology (Berl). 2002;162:29-36 pubmed
    ..Preceding open trials may help in the design of double-blind studies. ..
  14. van der Elst M, Wunderink Y, Ellenbroek B, Cools A. Differences in the cellular mechanism underlying the effects of amphetamine on prepulse inhibition in apomorphine-susceptible and apomorphine-unsusceptible rats. Psychopharmacology (Berl). 2007;190:93-102 pubmed
    ..This might provide an explanation for the increased dopamine release after this psychostimulant drug in patients vs controls. ..
  15. Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophr Bull. 1991;17:289-309 pubmed
    ..principal classes of new, established, and potential antipsychotics: (1) Antipsychotics such as sulpiride and remoxipride that block a subgroup of dopamine (DA) D2/D3 receptors produce a relatively low level of side effects, ..
  16. Andersson K, Fuxe K, Eneroth P, Harfstrand A, Agnati L. Involvement of D1 dopamine receptors in the nicotine-induced neuro-endocrine effects and depletion of diencephalic catecholamine stores in the male rat. Neuroendocrinology. 1988;48:188-200 pubmed
    ..1-3.0 mg/kg, i.p.), or with the D2 DA receptor antagonists remoxipride and raclopride (1 mg/kg, i.p.), or with the 5-hydroxytryptamine 2 (5-HT2) receptor antagonist ketanserin (0...
  17. Guinetdinov R, Bogdanov M, Kudrin V, Rayevsky K. Remoxipride and raclopride differ from metoclopramide by their effects on striatal dopamine release and biosynthesis in rats. Neuropharmacology. 1994;33:215-9 pubmed
    Effects of new neuroleptics remoxipride (2.4 mg/kg, i.p.) and raclopride (1.2 mg/kg, i.p.) in comparison to metoclopramide (5 mg/kg, i.p...
  18. Lang A, Sandor P, Duff J. Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995;18:39-45 pubmed
    b>Remoxipride is a novel substituted benzamide that more effectively blocks mesolimbic than striatal D2 dopamine receptors...
  19. Labelle A, Boulay L, Lapierre Y. Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia. Can J Psychiatry. 1999;44:887-92 pubmed
    ..Also, the PCT group had significantly more psychopathology at screening than did the NPCT group. Differences in retention rates between PCTs and NPCTs cannot be uniquely attributed to placebo itself. ..
  20. Basta Kaim A, Budziszewska B, Jaworska Feil L, Tetich M, Leskiewicz M, Kubera M, et al. Chlorpromazine inhibits the glucocorticoid receptor-mediated gene transcription in a calcium-dependent manner. Neuropharmacology. 2002;43:1035-43 pubmed
    ..while haloperidol acted only in high concentrations, and other antipsychotic drugs (sulpiride, raclopride, remoxipride) were without any effect...
  21. Chiou R, Lo M. Determination of remoxipride in human plasma and urine by reversed-phase ion-pair high-performance liquid chromatography. J Chromatogr. 1992;581:300-5 pubmed
    A sensitive method is described for the measurement of remoxipride in human plasma and urine. Remoxipride and its internal standard are extracted from plasma or urine at pH 12 with a mixture of hexane and methyl tert.-butyl ether...
  22. Brent P. Similar behavioural effects of sigma agonists and PCP-like non-competitive NMDA antagonists in guinea-pigs. Psychopharmacology (Berl). 1991;105:421-7 pubmed
    ..The results demonstrating behavioural depression were in contrast to the stimulatory effects of these drugs at similar doses in other rodent species.(ABSTRACT TRUNCATED AT 250 WORDS) ..
  23. Keks N, McGrath J, Lambert T, Catts S, Vaddadi K, Burrows G, et al. The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia. Acta Psychiatr Scand. 1994;90:358-65 pubmed
    A double-blind, randomized study of parallel group design comparing remoxipride and thioridazine (dose range 150-600 mg/day of either drug) was undertaken at 11 Australian centres...
  24. Ogawa T, Seki S, Masuda H, Igawa Y, Nishizawa O, Kuno S, et al. Dopaminergic mechanisms controlling urethral function in rats. Neurourol Urodyn. 2006;25:480-9 pubmed
    ..D1- and D2-like receptor agonists (SKF38393 and quinpirole, respectively) and antagonists (SCH23390 and remoxipride, respectively). Quinpirole (0.03, 0.1, and 0.3 mg/kg i.v...
  25. Amit Z, Smith B. Remoxipride, a specific D2 dopamine antagonist: an examination of its self-administration liability and its effects on d-amphetamine self-administration. Pharmacol Biochem Behav. 1992;41:259-61 pubmed
    The self-administration liability of remoxipride, a specific dopamine D2 antagonist, by laboratory rats was evaluated using an intravenous self-administration paradigm...
  26. Ross S. Heterogenous binding of 3H-remoxipride to membranes of rat liver and brain. Pharmacol Toxicol. 1995;76:29-35 pubmed
    The binding of the antipsychotic agent 3H-remoxipride to membranes of rat liver and brain (whole brain and cerebellum) was studied with filtration technique...
  27. Díaz E, Silva M, Israel A. Role of brain dopaminergic system in the adrenomedullin-induced diuresis and natriuresis. Pharmacol Res. 2003;48:489-96 pubmed
    ..Selective D(2) DA receptor antagonism with haloperidol, sulpiride, and remoxipride; or with the D(1) DA receptor antagonist, SCH 23390, blunted the increase in urinary volume and sodium ..
  28. Stevens J, Ploeger B, van der Graaf P, Danhof M, de Lange E. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos. 2011;39:2275-82 pubmed publisher
    ..The selective dopamine-D2 receptor antagonist remoxipride was administered at different dosages, in freely moving rats, by the IN and intravenous (IV) route...
  29. Eaton M, Tian Y, Lookingland K, Moore K. Remoxipride and raclopride differentially alter the activity of incertohypothalamic dopaminergic neurons. Neuropharmacology. 1992;31:1121-6 pubmed
    ..S-(-)-3,5-dichloro-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-hydroxy- 6-methoxybenzamide(+)-tartrate) and remoxipride (S(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2, 6-dimethoxybenzamide hydrochloride monohydrate), were ..
  30. Fagan D, Scott D, Mitchell M, Tiplady B. Effects of remoxipride on measures of psychological performance in healthy volunteers. Psychopharmacology (Berl). 1991;105:225-9 pubmed
    The acute psychomotor effects after oral doses of 30, 60 and 120 mg remoxipride, a new selective D2 receptor blocker, and placebo were investigated in a double-blind crossover study in 11 healthy male volunteers...
  31. Johansson C, Jackson D, Svensson L. The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology (Berl). 1994;116:437-42 pubmed
    The effect of various typical (haloperidol) and atypical (clozapine, raclopride, remoxipride) antipsychotics on phencyclidine (PCP)-induced disruption of sensorimotor gating was tested in rats using an acoustic startle paradigm...
  32. Lewander T. Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride. Acta Psychiatr Scand Suppl. 1994;380:64-7 pubmed
    b>Remoxipride is a selective dopamine D2 antagonist with virtually no activity on other transmitter receptors. It antagonizes dopamine agonists within a wide dose range in animals when it does not cause sedation or akinesia...
  33. Monnet F. [Involvement of sigma receptors in schizophrenic syndromes. Pathophysiological approach]. Presse Med. 1993;22:218-23 pubmed
    ..This hypothesis is further supported by the use of the sigma ligands rimcazole, BMY-14802 and remoxipride as effective antipsychotic agents...
  34. Braszko J. D2 dopamine receptor blockade prevents cognitive effects of Ang IV and des-Phe6 Ang IV. Physiol Behav. 2006;88:152-9 pubmed
    ..recognition] were evaluated in rats either pretreated or not with a selective D2 dopamine receptor antagonist remoxipride {(S)-(-)-3-Bromo-N-[(1-ethyl-2-pyrrolidinylOmethyl]2,6-dimethoxybenzamide hydrochloride}...
  35. Movin Osswald G, Hammarlund Udenaes M. Remoxipride: pharmacokinetics and effect on plasma prolactin. Br J Clin Pharmacol. 1991;32:355-60 pubmed
    1. The pharmacokinetics of remoxipride, a new neuroleptic, were investigated in 15 healthy subjects after an intravenous infusion of 50 mg, an intramuscular injection of 100 mg and after administration of two immediate release capsules (..
  36. Chouinard G. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatr Scand Suppl. 1990;358:111-9 pubmed
    We carried out a four-week double-blind placebo-controlled study comparing remoxipride (n = 20) to chlorpromazine (n = 21) and placebo (n = 21) in the treatment of newly admitted schizophrenic patients with acute exacerbation...
  37. Clark C, Smith F, Clark M, Garcia Roura L. Liquid chromatographic studies on the aqueous solution conformation of substituted benzamides related to remoxipride. J Chromatogr Sci. 1990;28:93-6 pubmed
    A series of disubstituted benzamides related to the sterically hindered 2,6-dimethoxybenzamide drugs, such as remoxipride, are prepared...
  38. Westlind Danielsson A, Gustafsson K, Andersson I. Remoxipride shows low propensity to block functional striatal dopamine D2 receptors in vitro. Eur J Pharmacol. 1994;288:89-95 pubmed
    The effect of remoxipride ((S)(-)3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenzam ide) on dopamine D2 receptor-mediated inhibition of cAMP formation in rat striatal tissues pieces was established together with that of a ..
  39. Robertsson B, Karlsson I, Eriksson L, Olsson J, Olofsson H, Jacobsson N, et al. An atypical neuroleptic drug in the treatment of behavioural disturbances and psychotic symptoms in elderly people. Dementia. 1996;7:142-6 pubmed
    The present study is a retrospective study of remoxipride therapy. A total of 103 patients, 65 years or older, with a DSM-III-R diagnosis of dementia or delirium, were included...
  40. Ongini E, Bo P, Dionisotti S, Trampus M, Savoldi F. Effects of remoxipride, a dopamine D-2 antagonist antipsychotic, on sleep-waking patterns and EEG activity in rats and rabbits. Psychopharmacology (Berl). 1992;107:236-42 pubmed
    The antipsychotic remoxipride, a selective dopamine D-2 receptor antagonist, was studied for its effects on sleep-waking patterns in the rat and electroencephalographic (EEG) activity in the rabbit...
  41. von Bahr C, Movin G, Yisak W, Jostell K, Widman M. Clinical pharmacokinetics of remoxipride. Acta Psychiatr Scand Suppl. 1990;358:41-4 pubmed
    The clinical pharmacokinetics of remoxipride, a pure enantiomer, have been studied in healthy volunteers and patients. After oral administration the drug is rapidly and almost completely absorbed with a bioavailability above 90%...
  42. Liu K, Lung F. [Difference in prolaction response of schizophrenic patients to equivalent doses of haloperidol, remoxipride and sulpiride]. Kaohsiung J Med Sci. 1996;12:685-90 pubmed
    ..medicine for more than two weeks, subjects were treated respectively with fixed doses of haloperidol (20 mg), remoxipride (450 mg), and sulpiride (1800 mg). During hospitalization, an assigned senior resident used Nancy O...
  43. Den Boer J, Ravelli D, Huisman J, Ohrvik J, Verhoeven W, Westenberg H. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacology (Berl). 1990;102:76-84 pubmed
    In the present 6-week double-blind, randomised, multicentre study, the atypical neuroleptic remoxipride was compared to haloperidol in acute schizophrenic patients (DSM-III)...
  44. Kohler C, Hall H, Magnusson O, Lewander T, Gustafsson K. Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatr Scand Suppl. 1990;358:27-36 pubmed
    In vitro receptor ligand binding studies in the rat showed that remoxipride displaced different radioligands at the dopamine D2, but not the D1 receptor...
  45. Yisak W, Farde L, von Bahr C, Nilsson L, Fredriksson G, Ogenstad S. Interaction study between remoxipride and biperiden. Psychopharmacology (Berl). 1993;111:27-32 pubmed
    ..male volunteers took part in a double-blind randomised cross-over study composed of three treatment sessions: remoxipride 100 mg; remoxipride 100 mg plus biperiden 4 mg; and biperiden 4 mg...
  46. Farde L, Grind M, Nilsson M, Ogenstad S, Sedvall G. Remoxipride--a new potential antipsychotic drug. Pharmacological effects and pharmacokinetics following repeated oral administration in male volunteers. Psychopharmacology (Berl). 1988;95:157-61 pubmed
    b>Remoxipride, a new potential antipsychotic drug, was administered over 4 days at two dose levels, 70 and 140 mg t.i.d., to eight healthy male volunteers...
  47. Movin Osswald G, Boelaert J, Hammarlund Udenaes M, Nilsson L. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function. Br J Clin Pharmacol. 1993;35:615-22 pubmed
    1. The pharmacokinetics of remoxipride, a new neuroleptic, were investigated in an open study with three parallel groups...
  48. Consolo S, Baronio P, Guidi G, Di Chiara G. Role of the parafascicular thalamic nucleus and N-methyl-D-aspartate transmission in the D1-dependent control of in vivo acetylcholine release in rat striatum. Neuroscience. 1996;71:157-65 pubmed
    ..1 mg/kg i.p.), also prevented the acetylcholine-increasing effect of the neuroleptic remoxipride (10 mg/kg s.c.), an effect known to be D1 receptor dependent...
  49. Varvel S, Vann R, Wise L, Philibin S, Porter J. Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology (Berl). 2002;160:182-91 pubmed
    ..However, a theoretical framework and adequate preclinical models have not yet been developed to predict or explain differences among the atypical antipsychotics, a necessary component of future development...
  50. Salehpour M, Forsgard N, Possnert G. FemtoMolar measurements using accelerator mass spectrometry. Rapid Commun Mass Spectrom. 2009;23:557-63 pubmed publisher
    ..Using 50 microL human blood plasma aliquots, we have demonstrated concentration measurements below 20 fM, containing sub-amol amounts of the labeled drug. The method has the immediate potential of operating in the sub-fM region...
  51. Nilsson C, Eriksson E. Effects of remoxipride and raclopride on prolactin release from clonal pituitary tumour cells. Pharmacol Toxicol. 1995;76:85-8 pubmed
    The dopamine D2 receptor antagonist remoxipride (30 microM) stimulated prolactin release from the prolactin-producing rat pituitary tumour cell strains GH3 and GH4C1 as well as from transfected GH4C1 cells expressing the short isoform of ..
  52. Brent P, Chahl L. Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma binding sites. Eur Neuropsychopharmacol. 1993;3:23-32 pubmed
    ..c.) and MK-801 (0.025, 0.1 and 1 mg/kg s.c.), 'atypical' neuroleptic drugs with (remoxipride 25 mg/kg s.c.) and without (raclopride 10 mg/kg s.c.; clozapine 25 mg/kg s.c...
  53. Holm A, Edsman I, Lundberg T, Odlind B. Tolerability of remoxipride in the long term treatment of schizophrenia. An overview. Drug Saf. 1993;8:445-56 pubmed
    ..Manual of Mental Disorders (DSM-III) criteria, were included in a long term treatment programme with remoxipride, a selective dopamine (D2)-receptor antagonist...
  54. Schlicker E, Marr I. The moderate affinity of clozapine at H3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics. Naunyn Schmiedebergs Arch Pharmacol. 1996;353:290-4 pubmed
    ..and of five atypical neuroleptics, chemically related (olanzapine) or unrelated to clozapine (remoxipride, risperidone, thioridazine, zotepine), at H3 receptors...
  55. Main D, Waterman A, Kilpatrick I. Behavioural analysis of changes in nociceptive thresholds produced by remoxipride in sheep and rats. Eur J Pharmacol. 1995;287:221-31 pubmed
    The antinociceptive potential of remoxipride was investigated in sheep and rats with concurrent motor function assessments...
  56. Hillefors M, von Euler G. Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen. Neurochem Int. 2001;38:31-42 pubmed
    ..128907, quinpirole, and bromocriptine, and antagonists such as haloperidol, raclopride, clozapine, GR 218231x, remoxipride, and U99194A...
  57. Manahan Vaughan D, Kulla A. Regulation of depotentiation and long-term potentiation in the dentate gyrus of freely moving rats by dopamine D2-like receptors. Cereb Cortex. 2003;13:123-35 pubmed
    ..The agonist effects on depotentiation were prevented by the D2-like antagonist remoxipride. Remoxipride itself did not influence basal synaptic transmission or depotentiation...
  58. Sedvall G. Monoamines and schizophrenia. Acta Psychiatr Scand Suppl. 1990;358:7-13 pubmed
    ..abstract truncated at 250 words)..
  59. McCreadie R, Todd N, Livingston M, Eccleston D, Watt J, Tait D, et al. A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. Acta Psychiatr Scand. 1988;78:49-56 pubmed
    This is the first comparative double blind study of remoxipride. Sixty-one patients with acute schizophrenia received either remoxipride (75-375 mg daily) or thioridazine (150-750 mg daily) for 6 weeks...
  60. Busatto G, Pilowsky L, Costa D, Ell P, Verhoeff N, Kerwin R. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl). 1995;117:55-61 pubmed
    Risperidone and remoxipride are recently introduced atypical antipsychotics, with clinical efficacy comparable to that of classical antipsychotics but lower propensity to induce extrapyramidal side effects (EPS)...
  61. Ogren S, Goldstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology. 1994;11:167-77 pubmed
    The dopamine (DA) D2 agonist quinpirole and the D2 receptor antagonists, haloperidol, raclopride, and remoxipride, were examined for their ability to block the locomotion induced by the noncompetitive N-methyl-D-aspartate (NMDA) receptor ..
  62. Norman M, Kelley J, Hollingsworth E. Conformationally restricted analogues of remoxipride as potential antipsychotic agents. J Med Chem. 1993;36:3417-23 pubmed
    ..restricted derivatives of (S)-3-bromo-N-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide (remoxipride) were synthesized and evaluated in vitro for their ability to inhibit [3H]raclopride binding at the dopamine D-..
  63. Klieser E, Strauss W, Lemmer W. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta Psychiatr Scand Suppl. 1994;380:68-73 pubmed
    b>Remoxipride and clozapine are new neuroleptics that are thought to be superior to the substances in use by their efficacy and tolerance...
  64. Bezu M, Maliković J, Kristofova M, Engidawork E, Hoger H, Lubec G, et al. Spatial Working Memory in Male Rats: Pre-Experience and Task Dependent Roles of Dopamine D1- and D2-Like Receptors. Front Behav Neurosci. 2017;11:196 pubmed publisher
    ..ICV) application of a D1R-like (SKF81297) and D2R-like agonist (Sumanirole) and antagonist (SCH23390, Remoxipride) at a low and high dose through 3 days of training...
  65. Eaton M, Tian Y, Lookingland K, Moore K. Comparison of the effects of remoxipride and raclopride on nigrostriatal and mesolimbic dopaminergic neuronal activity and on the secretion of prolactin and alpha-melanocyte-stimulating hormone. Neuropsychopharmacology. 1992;7:205-11 pubmed
    Raclopride and remoxipride, which are reported to be selective dopamine-D2 antagonists, are currently under clinical investigation as antipsychotic drugs...
  66. Westlind Danielsson A, Ericsson G, Sandell L, Elinder F, Arhem P. High concentrations of the neuroleptic remoxipride block voltage-activated Na+ channels in central and peripheral nerve membranes. Eur J Pharmacol. 1992;224:57-62 pubmed
    The actions of the neuroleptic compounds remoxipride, haloperidol and (-)-sulpiride on Na+ and K+ ion current flow were examined in rat CNS and frog PNS, using 86Rb+ ion flux and voltage-clamp techniques, respectively...
  67. Georgieva J, Mohringe B, Magnusson O. Neurochemical effects of prolonged treatment with remoxipride as assessed by intracerebral microdialysis in freely moving rats. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:1187-201 pubmed
    ..2. Microdialysis session 1. A single s.c. injection of remoxipride (40 mumol/kg), resulted in increased dialysate concentrations of dopamine, DOPAC and HVA. 3...
  68. Ogren S, Lundstrom J, Nilsson L. Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile. J Neural Transm Gen Sect. 1993;94:199-216 pubmed
    The cataleptic effect of remoxipride was examined in the horizontal bar test after i.v.,i.p. and s.c. administration to male rats. Remoxipride induced immediate catalepsy after high i.v...
  69. Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry. 1998;59:644-56 pubmed
    ..This article reviews the published clinical experience with atypical neuroleptics in children and adolescents...
  70. Christian A, Goodwin A, Baker L. Antagonism of the discriminative stimulus effects of (+)-7-OH-DPAT by remoxipride but not PNU-99194A. Pharmacol Biochem Behav. 2001;68:371-7 pubmed
    ..However, the D(2) antagonist remoxipride (3.0 mg/kg) produced a rightward shift in the (+)-7-OH-DPAT dose-response curve...
  71. Chlan Fourney J, Ashe P, Nylen K, Juorio A, Li X. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. 2002;954:11-20 pubmed
  72. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Anticonvulsant action of GBR-12909 and citalopram against acute experimentally induced limbic seizures. Neuropharmacology. 2004;47:1053-61 pubmed
    ..Non-selective actions curtailing glutamatergic activity may further be responsible for the unexpected anticonvulsant effects at predicted proconvulsant concentrations...
  73. Hebenstreit G, Laux G, Schubert H, Beckmann H, Amman J, Bunse J, et al. A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia. Pharmacopsychiatry. 1991;24:153-8 pubmed
    A double-blind multicentre study comparing the efficacy and safety of remoxipride in controlled-release formulation (REM-CR), given once a day, and immediate-release formulation (REM-IR) and haloperidol, given twice daily, was conducted ..
  74. Den Boer J, Ravelli D, Huisman J, Ohrvik J, Verhoeven W, Westenberg H. A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia. Acta Psychiatr Scand Suppl. 1990;358:108-10 pubmed
    ..patients were entered into a multicentre, double-blind randomized study to compare the efficacy and safety of remoxipride with those of haloperidol in the acute treatment of schizophrenia or schizophreniform disorder...
  75. Walinder J, Holm A. Experiences of long-term treatment with remoxipride: efficacy and tolerability. Acta Psychiatr Scand Suppl. 1990;358:158-63 pubmed
    An international clinical trial programme was undertaken to evaluate the clinical safety and tolerability of remoxipride during a 12 month long-term study and to evaluate safety, tolerability and efficacy of remoxipride for up to 6 ..
  76. Hillefors Berglund M, von Euler G. Pharmacology of dopamine D3 receptors in the islands of Calleja of the rat using quantitative receptor autoradiography. Eur J Pharmacol. 1994;261:179-83 pubmed
    ..was R(-)-propylnorapomorphine > 7-OH-DPAT approximately haloperidol > raclopride > dopamine > remoxipride. Remoxipride injected in vivo (0.03-100 mumol/kg i.p...
  77. Mohell N, Sallemark M, Rosqvist S, Malmberg A, Hogberg T, Jackson D. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. Eur J Pharmacol. 1993;238:121-5 pubmed
    The substituted benzamide, remoxipride, is a new atypical antipsychotic agent with good clinical efficacy and low extrapyramidal side-effect potential...
  78. Sams Dodd F. Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol. 1997;8:196-215 pubmed
    ..In the present study the effects of the novel antipsychotics remoxipride (2.5-20 mg/kg), risperidone (0.02-0.63 mg/kg), sertindole (0.01-2.5 mg/kg), olanzapine (0.16-2...
  79. Ericson H, Ross S. Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain. Eur J Pharmacol. 1992;226:157-61 pubmed
    The effects of 14 days' treatment of rats with haloperidol, remoxipride or both combined on the sigma binding sites in whole brain and liver were determined. The compounds were given subcutaneously via osmotic minipumps at a dose of 0...
  80. Pellissier G, Demenge P. Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists. J Cardiovasc Pharmacol. 1991;18:548-55 pubmed
    ..Apomorphine-induced hypotension was competitively antagonized by either SCH 23390 or remoxipride, selective D1- and D2-receptor antagonists, respectively, but only remoxipride antagonized the bradycardia...
  81. Gerlach J, Casey D. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:103-12 pubmed
    ..6 with mild spontaneous oral dyskinesia (tongue protrusions), were tested with two dopamine D2 antagonists, remoxipride (a new substituted benzamide) and haloperidol, and with two dopamine agonists, methylphenidate and apomorphine...
  82. Bertorelli R, Consolo S. D1 and D2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. J Neurochem. 1990;54:2145-8 pubmed
    ..2 mg/kg, i.p., whereas the D2 antagonists (-)-remoxipride (10 mg/kg, s.c.) and L-sulpiride (50 mg/kg, i.p...
  83. Den Boer J, Westenberg H. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol. Psychopharmacol Bull. 1990;26:99-107 pubmed
    In the present double-blind study comprising 6 weeks, remoxipride was compared with haloperidol in acute schizophrenic patients (DSM-III)...
  84. Movin G, Gustafson L, Franzen G, Widerlov E, Soni S, Tench D, et al. Pharmacokinetics of remoxipride in elderly psychotic patients. Acta Psychiatr Scand Suppl. 1990;358:176-80 pubmed
    The pharmacokinetics of remoxipride when given as single doses of 50 mg and repeated doses of 50 mg, 100 mg, and 200 mg twice daily to 10 elderly psychotic patients (71-89 years) were compared with the findings of two other studies to ..
  85. Patris M, Agussol P, Alby J, Brion S, Burnat G, Castelnau D, et al. A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. Acta Psychiatr Scand Suppl. 1990;358:78-82 pubmed
    ..schizophrenia were admitted to a double-blind randomized multicentre trial in which the efficacy and safety of remoxipride at two dose levels was compared with those of haloperidol...
  86. Trimble K, Bell R, King D. Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride. Pharmacol Biochem Behav. 1997;56:809-16 pubmed
    ..Disrupted LI has been suggested as an animal model for the attentional deficits observed in schizophrenia. Remoxipride, a selective dopamine D, antagonist, is an effective antipsychotic with an atypical clinical profile...
  87. Reeves R, Thiruchelvam M, Cory Slechta D. Expression of behavioral sensitization to the cocaine-like fungicide triadimefon is blocked by pretreatment with AMPA, NMDA and DA D1 receptor antagonists. Brain Res. 2004;1008:155-67 pubmed
    ..could be prevented by the DA D1-like receptor antagonist SCH 23390 (SCH), the DA D2-like receptor antagonist remoxipride (Rem), the competitive NMDA antagonist CPP, or the AMPA antagonist NBQX...
  88. Lapierre Y, Nair N, Chouinard G, Awad A, Saxena B, Jones B, et al. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Acta Psychiatr Scand Suppl. 1990;358:72-7 pubmed
    The efficacy and side-effect profile for three dose ranges of remoxipride were compared with haloperidol in 242 schizophrenic inpatients in 13 centres...
  89. Wadworth A, Heel R. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia. Drugs. 1990;40:863-79 pubmed
    b>Remoxipride is a substituted benzamide of the same class as sulpiride, and has a pharmacodynamic profile consistent with central antidopaminergic activity...
  90. Morio Y, Tanimoto H, Yakushiji T, Morimoto Y. Characterization of the currents induced by sigma ligands in NCB20 neuroblastoma cells. Brain Res. 1994;637:190-6 pubmed
    ..was bromperidol > haloperidol > mosapramine = clocapramine > carpipramine > chlorpromazine > remoxipride > naloxone...
  91. Rammsayer T. Are there dissociable roles of the mesostriatal and mesolimbocortical dopamine systems on temporal information processing in humans?. Neuropsychobiology. 1997;35:36-45 pubmed
    ..information processing in humans, the effects of the 3 mg of haloperidol, 300 mg of sulpiride, and 150 mg of remoxipride were studied in a placebo-controlled double-blind experiment...
  92. Depoortere R, Perrault G, Sanger D. Some, but not all, antipsychotic drugs potentiate a low level of prepulse inhibition shown by rats of the Wistar strain. Behav Pharmacol. 1997;8:364-72 pubmed
    ..In contrast, the antipsychotics risperidone, amisulpride, raclopride and remoxipride did not potentiate PPI...